Eli Lilly and Company
LLY
$917.65
-0.42%
Eli Lilly and Company is a global pharmaceutical leader focused on developing and commercializing medicines across key therapeutic areas, including cardiometabolic health, immunology, neuroscience, and oncology. The company is a dominant market leader, particularly distinguished by its blockbuster GLP-1 drugs for diabetes and obesity, which have positioned it at the forefront of one of the most significant healthcare markets in decades. The current investor narrative is overwhelmingly centered on Lilly's explosive growth driven by its weight-loss drugs Mounjaro and Zepbound, with intense debate focusing on its ability to maintain market leadership against new competitive entrants, manage supply constraints, and successfully integrate strategic acquisitions to expand its pipeline.…
LLY
Eli Lilly and Company
$917.65
Related headlines
LLY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1192.94 and implied upside of +30.0% versus the current price.
Average Target
$1192.94
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$734 - $1193
Analyst target range
Analyst coverage for Eli Lilly is extensive, with 11 analysts providing estimates, and the institutional sentiment remains overwhelmingly bullish, as evidenced by recent actions from major firms like JP Morgan, Morgan Stanley, and Wells Fargo reiterating Overweight/Buy ratings in February 2026. The consensus revenue estimate for the upcoming period is $126.41 billion, with a wide range from $116.28 billion to $135.30 billion, reflecting some uncertainty around the exact trajectory of drug launches and competitive dynamics. While a specific consensus price target is not provided in the data, the wide range of revenue estimates and the recent mix of Buy/Hold/Reduce actions (including a Reduce from HSBC in March 2026) suggest that while the bullish thesis is dominant, there is debate around the stock's near-term valuation after its historic run.
Bulls vs Bears: LLY Investment Factors
The bullish case for Eli Lilly, anchored in its phenomenal 42.6% revenue growth and expanding 85% gross margins, currently holds stronger evidence due to the tangible, near-term financial results from its GLP-1 franchise. However, the bearish concerns around its premium valuation and competitive threats are gaining traction, as evidenced by the stock's recent 14% YTD decline and significant underperformance versus the market. The single most important tension in the investment debate is whether Lilly's explosive earnings growth over the next 12-18 months will be sufficient to justify and sustain its elevated valuation multiple in the face of intensifying competition and potential market saturation fears. The resolution of this growth-vs-valuation dynamic will dictate the stock's direction.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 42.6% YoY to $19.29 billion, driven by the Cardiometabolic segment's $13.18 billion in sales. This demonstrates the blockbuster success of GLP-1 drugs Mounjaro and Zepbound, positioning Lilly in a multi-decade growth market.
- Exceptional Profitability & Margins: Q4 gross margin expanded to 85.05% from 82.54% a year ago, and net margin reached 34.4%. This operating leverage, coupled with a Return on Equity of 77.78%, shows the company's ability to convert massive sales growth into superior profitability.
- Strong Forward Earnings Growth: The forward P/E of 22.02x is less than half the trailing P/E of 46.76x, implying the market expects massive near-term earnings growth. The PEG ratio of 0.49 suggests the stock is undervalued relative to its expected growth rate.
- Robust Cash Flow & Financial Health: Trailing twelve-month free cash flow is $8.97 billion, providing ample resources for R&D, acquisitions, and shareholder returns. A current ratio of 1.58 indicates strong short-term liquidity to fund operations.
Bearish
- Valuation Compression & Pullback: The stock is down 14.19% YTD and 10.73% over 3 months, significantly underperforming the S&P 500. Trading at 82% of its 52-week high, this suggests a correction from peak optimism and potential valuation compression.
- Premium Valuation vs. Peers: A forward P/E of 22x is a substantial premium to large-cap pharma peers, which typically trade in the mid-teens. This premium leaves the stock vulnerable to multiple contraction if growth expectations falter.
- Rising Competitive Threats: Recent news highlights a surge in competitive activity, including the largest biotech IPO since 2021 (Kailera Therapeutics) and advanced pipeline candidates from rivals like Viking Therapeutics. This intensifies the long-term risk to Lilly's market share.
- High Financial Leverage: A debt-to-equity ratio of 1.60 reflects a leveraged capital structure used to fund growth and buybacks. While cash flow is strong, this leverage increases financial risk in a rising interest rate environment.
LLY Technical Analysis
The stock is in a pronounced downtrend from its recent highs, having declined 10.73% over the last three months and 14.19% year-to-date, which contrasts with a still-positive 10.37% gain over the past year. Currently trading at $927.03, the price sits at approximately 82% of its 52-week range (high: $1133.95, low: $623.78), indicating a significant retreat from peak levels but remaining well above its lows, suggesting a correction within a longer-term uptrend rather than a structural breakdown. Recent momentum shows a modest 0.98% gain over the past month, which is a notable underperformance compared to the S&P 500's 7.36% rise, as evidenced by a negative 1-month relative strength of -6.38; this divergence signals the stock is undergoing a period of consolidation and relative weakness after its massive prior rally. Key technical support is anchored at the 52-week low of $623.78, while immediate overhead resistance is at the recent high of $1133.95; a sustained break below the recent March low near $878 could signal a deeper correction, whereas reclaiming the $1,000 level would suggest renewed bullish momentum. With a beta of 0.504, the stock exhibits significantly lower volatility than the broader market, which has provided some downside cushion during the recent pullback but also implies it may not fully participate in sharp market rallies.
Beta
0.50
0.50x market volatility
Max Drawdown
-30.4%
Largest decline past year
52-Week Range
$624-$1134
Price range past year
Annual Return
+10.6%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +1.6% | +8.5% |
| 3m | -13.8% | +2.8% |
| 6m | +11.2% | +4.6% |
| 1y | +10.6% | +32.3% |
| ytd | -15.1% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is exceptionally strong and accelerating, with Q4 2025 revenue of $19.29 billion representing a massive 42.6% year-over-year increase, and sequential quarterly revenue has climbed steadily from $12.73 billion in Q1 to the current level. The growth is overwhelmingly driven by the Cardiometabolic Health segment, which contributed $13.18 billion in the latest period, fueled by the phenomenal success of GLP-1 agonists Mounjaro and Zepbound. Profitability is robust and expanding, with Q4 net income of $6.64 billion and a gross margin of 85.05%, which has improved from 82.54% in the year-ago quarter; the net margin for the quarter was 34.4%, demonstrating significant operating leverage as sales scale. The company's balance sheet and cash flow are solid, with trailing twelve-month free cash flow of $8.97 billion, a current ratio of 1.58 indicating healthy short-term liquidity, and a return on equity of an exceptional 77.78%. However, the debt-to-equity ratio of 1.60 reflects the leveraged capital structure used to fund growth and shareholder returns, including substantial stock repurchases, but the strong cash generation provides ample coverage for debt obligations.
Quarterly Revenue
$19.3B
2025-12
Revenue YoY Growth
+0.42%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is elevated at 46.76x, while the forward PE is significantly lower at 22.02x; this wide gap reflects the market's expectation for massive earnings growth to materialize over the next year as GLP-1 drug sales continue to ramp. Compared to industry averages, Eli Lilly trades at a substantial premium; for instance, its forward PE of 22x is above typical large-cap pharma averages, which often range in the mid-teens, a premium justified by its superior growth profile and dominant position in the high-margin obesity market. Historically, the stock's current trailing PE of 46.76x is below its own peak multiples seen in recent quarters (e.g., 67.2x in Q1 2025) but remains well above its longer-term historical average, indicating that while some valuation compression has occurred, the stock still prices in highly optimistic future earnings expectations.
PE
46.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2221x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, the primary risk is the company's leveraged balance sheet, with a debt-to-equity ratio of 1.60, though this is mitigated by robust $9.0 billion annual free cash flow. Operational risk is concentrated in the overwhelming dependence on the Cardiometabolic segment (68% of Q4 revenue), making the company vulnerable to any slowdown in GLP-1 drug demand, supply chain issues, or unexpected clinical setbacks for pipeline candidates like retatrutide. Earnings volatility is a lesser concern given the current growth trajectory, but the high fixed-cost nature of pharma R&D means any revenue disappointment would disproportionately impact net income.
Market and competitive risks are elevated. Trading at a forward P/E of 22x, a premium to the pharma sector, the stock is exposed to valuation compression if growth decelerates or investor sentiment shifts away from premium-priced growth stocks. The competitive landscape is intensifying rapidly, as seen in the news of Kailera's massive IPO and Viking Therapeutics' advanced trials, which threaten long-term market share. Regulatory headwinds or pricing pressures, though not currently dominant, are perennial risks in healthcare. The stock's low beta of 0.50 suggests it is less correlated to broad market swings, but this may not protect it from sector-specific rotations.
The worst-case scenario involves a combination of faster-than-expected competitive encroachment, leading to market share loss and growth deceleration, coupled with a broader market de-rating of growth stocks. This could trigger a wave of analyst downgrades and a re-rating towards peer-average multiples. A realistic downside could see the stock fall to its 52-week low of $623.78, which would represent a loss of approximately -33% from the current price of $927.03. The historical maximum drawdown of -30.4% provides a similar benchmark for potential peak-to-trough decline in a severe adverse scenario.